

HOUSE BILL 103: 2022 Appropriations Act, Sec. 9D.8: Clarify Treatment of 340B Drugs / Address Reimbursement for Federally Qualified Health Centers

Committee: Date: August 16, 2022
Introduced by: Prepared by: Jennifer Hillman
Analysis of: Sec. 9D.8 of S.L. 2022-74
Staff Attorney

OVERVIEW: Section 9D.8 of S.L. 2022-74 amends Section 9D.19A of S.L. 2021-180 to clarify that there will be no changes to the reimbursement for drugs covered by the federal 340B Drug Pricing Program under prepaid health plan contracts for standard benefit plans through June 30, 2026. This section also provides \$4.4 million for temporary Medicaid reimbursement increases to federally qualified health centers (FQHCs) as a percentage above cost. By February 1, 2023, the Division of Health Benefits, Department of Health and Human Services, must collaborate with FQHCs to develop and submit to the Joint Legislative Oversight Committee on Medicaid and NC Health Choice a proposed comprehensive reimbursement structure for FQHCs that addresses pharmacy costs in the context of the overall financial challenges faced by FQHCs.

The changes related to 340B drugs became effective retroactively to November 18, 2021. The remainder of this section became effective July 1, 2022.

